Yue Xi

Yue Xi

Auto-generated profile, based on publicly available information

Yue Xi

Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2021 in Science Advances
Verified
Journal Article
Open access
YXYue Xi
Yue Xi
YLYanping Li
Yanping Li
PXPengfei Xu
Pengfei Xu
SLSihan Li
Sihan Li
ZLZhengsheng Liu
Zhengsheng Liu
WXWen Xie
Wen Xie
Pirfenidone inhibits HSC activation and liver fibrosis by targeting glutaredoxin-1 and reducing Smad3 glutathionylation.

25 September 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
HTHung-Chun Tung
Hung-Chun Tung
JKJong-Won Kim
Jong-Won Kim
JZJunjie Zhu
Junjie Zhu
SLSihan Li
Sihan Li
JYJiong Yan
Jiong Yan
WXWen Xie
Wen Xie
Activation of extracellular matrix–producing hepatic stellate cells (HSCs) is a key event in liver fibrogenesis. We showed that the expression of the heme-thiolate monooxygenase cytochrome P450 1B1 (CYP1B1) was elevated in human and mouse fibrotic livers and activated HSCs. Systemic or HSC-specific ablation and pharmacological inhibition of CYP1B1 attenuated HSC activation and protected male but not female mice from thioacetamide (TAA)–, carbon tetrachloride (CCl 4 )–, or bile duct ligation (BDL)–induced liver fibrosis. Metabolomic analysis revealed an increase in the disaccharide trehalose in CYP1B1-deficient HSCs resulting from intestinal suppression of the trehalose-metabolizing enzyme trehalase, whose gene we found to be a target of RARα. Trehalose or its hydrolysis-resistant derivative lactotrehalose exhibited potent antifibrotic activity in vitro and in vivo by functioning as an HSC-specific autophagy inhibitor, which may account for the antifibrotic effect of CYP1B1 inhibition. Our study thus reveals an endobiotic function of CYP1B1 in liver fibrosis in males, mediated by liver-intestine cross-talk and trehalose. At the translational level, pharmacological inhibition of CYP1B1 or the use of trehalose/lactotrehalose may represent therapeutic strategies for liver fibrosis.

1 January 2020 in Toxicology Letters
Verified
Journal Article
Closed access
YXYue Xi
Yue Xi
YZYunhui Zhang
Yunhui Zhang
JPJi Pan
Ji Pan
SCSirong Chen
Sirong Chen
SLShuhong Lu
Shuhong Lu
ZHZhiying Huang
Zhiying Huang

16 December 2023 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
PXPengfei Xu
Pengfei Xu
YXYue Xi
Yue Xi
JKJong-Won Kim
Jong-Won Kim
JZJunjie Zhu
Junjie Zhu
MZMin Zhang
Min Zhang
WXWen Xie
Wen Xie
Sulfation is a crucial and prevalent conjugation reaction involved in cellular processes and mammalian physiology. 3′-Phosphoadenosine 5′-phosphosulfate (PAPS) synthase 2 (PAPSS2) is the primary enzyme to generate the universal sulfonate donor PAPS. The involvement of PAPSS2-mediated sulfation in adenomatous polyposis coli (APC) mutation-promoted colonic carcinogenesis has not been reported. Here, we showed that the expression of PAPSS2 was decreased in human colon tumors along with cancer stages, and the lower expression of PAPSS2 was correlated with poor prognosis in advanced colon cancer. Gut epithelial-specific heterozygous Apc deficient and Papss2-knockout (ApcΔgut-HetPapss2Δgut) mice were created, and the phenotypes were compared to the spontaneous intestinal tumorigenesis of ApcΔgut-Het mice. ApcΔgut-HetPapss2Δgut mice were more sensitive to gut tumorigenesis, which was mechanistically accounted for by the activation of Wnt/β-catenin signaling pathway due to the suppression of chondroitin sulfation and inhibition of the farnesoid X receptor (FXR)-transducin-like enhancer of split 3 (TLE3) gene regulatory axis. Chondroitin sulfate supplementation in ApcΔgut-HetPapss2Δgut mice alleviated intestinal tumorigenesis. In summary, we have uncovered the protective role of PAPSS2-mediated chondroitin sulfation and bile acids–FXR–TLE3 activation in the prevention of gut carcinogenesis via the antagonization of Wnt/β-catenin signaling. Chondroitin sulfate may be explored as a therapeutic agent for Papss2 deficiency-associated colonic carcinogenesis.

24 October 2024 in Hepatology
Verified
Journal Article
Closed access
JKJong-Won Kim
Jong-Won Kim
HTHung-Chun Tung
Hung-Chun Tung
MKMengyun Ke
Mengyun Ke
PXPengfei Xu
Pengfei Xu
XCXinran Cai
Xinran Cai
WXWen Xie
Wen Xie
Background and Aims: Liver fibrosis is characterized by the progressive scarring of liver tissue. Oxidative stress is a critical causal factor of HSC activation and subsequent liver fibrogenesis, but the mechanism is not fully understood. Cysteine sulfinic acid (Cys-SO2H), a modification of reactive cysteine residues, is a unique form of oxidative response that alters the structure and function of proteins. Sulfiredoxin-1 (SRXN1) is responsible for the ATP-dependent reduction of the Cys-SO2H to sulfenic acid (Cys-SOH). Approach and Results: We found that the expression of SRXN1 was increased in activated HSCs and in human and mouse fibrotic livers. HSC-specific ablation of Srxn1 or pharmacological inhibition of Srxn1 exacerbated HSC activation and sensitized mice to liver fibrosis. Mechanistically, SRXN1 inhibited HSC activation by desulfinylating the phosphatase protein tyrosine phosphatase nonreceptor type 12 (PTPN12), which enhanced its phosphatase activity and protein stability, leading to decreased tyrosine phosphorylation and reduced activation of the profibrotic inflammasome protein NLRP3 (nucleotide-binding domain, leucine-rich–containing family, pyrin domain–containing-3). The antifibrotic effect of SRXN1 was abolished when NLRP3 was inhibited. In contrast, overexpression of PTPN12 attenuated NLRP3 activation, and this effect was further amplified by the C164A S-sulfinylation–resistant mutant of PTPN12. Conclusions: Our findings have uncovered an important role of SRXN1 and protein S-sulfinylation in HSC activation and liver fibrosis. The SRXN1-PTPN12-NLRP3 axis represents potential therapeutic targets for liver fibrosis.

18 February 2026 in Nature
Verified
Journal Article
Closed access
PDF file
YXYue Xi
Yue Xi
WZWaner Zeng
Waner Zeng
JLJie Luo
Jie Luo
JZJian Zhou
Jian Zhou
LWLin Wang
Lin Wang
BSBao-Liang Song
Bao-Liang Song